Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease
Does the drug gantenerumab help patients with Alzheimer's disease?
Basic Study Information
Purpose:Location: University of Rochester
This randomized, double-blind, placebo-controlled, parallel group study will evaluate
efficacy and safety of gantenerumab versus placebo in participants with early (prodromal
mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible
participants will be randomized 1:1 to receive either subcutaneous (SC) injection
gantenerumab or placebo. The primary efficacy assessment will be performed at the
end of the
double blind period at week 104. Participants will then be offered to enter into an
open-label extension (OLE). Participants not willing to go to the OLE will participate
long term follow-up period for up to 50 weeks after the last gantenerumab dose.
Study Contact InformationPhone: (888) 662-6728
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search